Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR)
Transplant International · 2026
DOI: 10.3389/ti.2025.15823 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Transplant International, 2026. Verfasst von Gaurav Gupta und 23 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Commonwealth University, Richmond, VA, United States. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Kidney Transplantation, Liver Transplantation, Heart Transplantation. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natera.
Abstract (Originalsprache)
Donor-derived cell free DNA (dd-cfDNA) is an established biomarker for detection of rejection in single organ transplants; data is limited in multi-organ transplant (MOT) recipients. “Use of dd-cfDNA in Multi-Organ Transplant Recipients” (MOTR) was a multicenter, prospective, cross-sectional study that assessed dd-cfDNA fraction (%) and donor quantity score (DQS, cp/mL) in pancreas-kidney (PKT), heart-kidney (HKT), and liver-kidney (LKT) recipients. We explored dd-cfDNA baseline levels across the different organ combinations, and compared them to kidney-only (KT) and heart-only (HT) transplant recipients. Among 347 MOT recipients from 18 sites (PKT = 183, HKT = 57, LKT = 107), most (88.2%) had simultaneous transplants. Median dd-cfDNA levels in PKT and HKT recipients were not significantly different from KT; median dd-cfDNA levels among HKT recipients were significantly higher than in HT recipients (p < 0.001). In LKT recipients, median dd-cfDNA was significantly higher compared to KT (p < 0.001). dd-cfDNA showed associations with organ impairment indicated by abnormal values of pancreatic and liver enzymes in PKT and LKT. As the largest multi-center study to date evaluating dd-cfDNA levels in MOT recipients, MOTR showed that organ-specific physiology affects dd-cfDNA levels across organ transplant combinations, laying the foundation for future efforts to use dd-cfDNA to assess organ-specific signatures of allograft injury in MOT recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Virginia Commonwealth University, Richmond, VA, United States.
- UT Southwestern Medical Center, Dallas, TX, United States.
- Western University, Schulich School of Medicine and Dentistry, London, ON, Canada.
- Baylor University Medical Center, Dallas, TX, United States.
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
- MedStar Georgetown University Hospital, Washington, DC, United States.
Förderung
- Natera
Zitieren
APA
Gupta, G., Wojciechowski, D., Sener, A., Gong, T., Dunn, T. B., Costa, N., Odorico, J. S., Daloul, R., Rohan, V. S., Biagini, D. G., Barnes, D., Kaur, N., Gude, G., Ahmed, E., Xie, J., Spellicy, C. J., Al Haj Baddar, N., Bloom, M. S., Demko, Z., …, & Akkina, S. K. (2026). Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR). Transplant International. https://doi.org/10.3389/ti.2025.15823
Vancouver
Gupta G, Wojciechowski D, Sener A, Gong T, Dunn TB, Costa N, et al. Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR). Transplant International. 2026. doi:10.3389/ti.2025.15823
BibTeX
@article{Gupta2026,
author = {Gupta, Gaurav and Wojciechowski, David and Sener, Alp and Gong, Timothy and Dunn, Ty B and Costa, Nadiesda and Odorico, Jon S and Daloul, Reem and Rohan, Vinayak S and Biagini, D Giovanni and Barnes, David and Kaur, Navchetan and Gude, Geethanjali and Ahmed, Ebad and Xie, Jing and Spellicy, Catherine J and Al Haj Baddar, Nour and Bloom, Michelle S and Demko, Zachary and Prewett, Adam and Gauthier, Phil and Bhorade, Sangeeta and Tabriziani, Hossein and Akkina, Sanjeev K},
title = {Donor-Derived Cell-Free DNA in Pancreas-Kidney, Heart-Kidney, and Liver-Kidney Multiorgan Transplant Recipients (MOTR)},
journal = {Transplant International},
year = {2026},
doi = {10.3389/ti.2025.15823}
}
EUVIMED